661 related articles for article (PubMed ID: 27434748)
1. Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.
Mateos MV; Granell M; Oriol A; Martinez-Lopez J; Blade J; Hernandez MT; Martín J; Gironella M; Lynch M; Bleickardt E; Paliwal P; Singhal A; San-Miguel J
Br J Haematol; 2016 Nov; 175(3):448-456. PubMed ID: 27434748
[TBL] [Abstract][Full Text] [Related]
2. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.
Richardson PG; Jagannath S; Moreau P; Jakubowiak AJ; Raab MS; Facon T; Vij R; White D; Reece DE; Benboubker L; Zonder J; Tsao LC; Anderson KC; Bleickardt E; Singhal AK; Lonial S;
Lancet Haematol; 2015 Dec; 2(12):e516-27. PubMed ID: 26686406
[TBL] [Abstract][Full Text] [Related]
3. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Lonial S; Dimopoulos M; Palumbo A; White D; Grosicki S; Spicka I; Walter-Croneck A; Moreau P; Mateos MV; Magen H; Belch A; Reece D; Beksac M; Spencer A; Oakervee H; Orlowski RZ; Taniwaki M; Röllig C; Einsele H; Wu KL; Singhal A; San-Miguel J; Matsumoto M; Katz J; Bleickardt E; Poulart V; Anderson KC; Richardson P;
N Engl J Med; 2015 Aug; 373(7):621-31. PubMed ID: 26035255
[TBL] [Abstract][Full Text] [Related]
4. Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study.
Iida S; Nagai H; Kinoshita G; Miyoshi M; Robbins M; Pandya D; Bleickardt E; Chou T
Int J Hematol; 2017 Mar; 105(3):326-334. PubMed ID: 27848182
[TBL] [Abstract][Full Text] [Related]
5. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial.
Dimopoulos MA; Lonial S; Betts KA; Chen C; Zichlin ML; Brun A; Signorovitch JE; Makenbaeva D; Mekan S; Sy O; Weisel K; Richardson PG
Cancer; 2018 Oct; 124(20):4032-4043. PubMed ID: 30204239
[TBL] [Abstract][Full Text] [Related]
6. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
Dimopoulos MA; Dytfeld D; Grosicki S; Moreau P; Takezako N; Hori M; Leleu X; LeBlanc R; Suzuki K; Raab MS; Richardson PG; Popa McKiver M; Jou YM; Shelat SG; Robbins M; Rafferty B; San-Miguel J
N Engl J Med; 2018 Nov; 379(19):1811-1822. PubMed ID: 30403938
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic and exposure-response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma.
Ide T; Osawa M; Sanghavi K; Vezina HE
Cancer Chemother Pharmacol; 2022 Jan; 89(1):129-140. PubMed ID: 34825942
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study.
Berdeja J; Jagannath S; Zonder J; Badros A; Kaufman JL; Manges R; Gupta M; Tendolkar A; Lynch M; Bleickardt E; Paliwal P; Vij R
Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):129-38. PubMed ID: 26795075
[TBL] [Abstract][Full Text] [Related]
9. A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.
Berenson J; Manges R; Badarinath S; Cartmell A; McIntyre K; Lyons R; Harb W; Mohamed H; Nourbakhsh A; Rifkin R
Am J Hematol; 2017 May; 92(5):460-466. PubMed ID: 28213943
[TBL] [Abstract][Full Text] [Related]
10. FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma.
Gormley NJ; Ko CW; Deisseroth A; Nie L; Kaminskas E; Kormanik N; Goldberg KB; Farrell AT; Pazdur R
Clin Cancer Res; 2017 Nov; 23(22):6759-6763. PubMed ID: 28249893
[TBL] [Abstract][Full Text] [Related]
11. Elotuzumab and dexamethasone for relapsed or refractory multiple myeloma patients: A retrospective study.
Gross Z; Rahbari A; Wirtschafter E; Spektor TM; Udd KA; Bujarski S; Ghermezi M; Nosrati JD; Vidisheva A; Eades B; Cecchi G; Maluso T; Swift R; Berenson JR
Eur J Haematol; 2018 Jun; 100(6):621-623. PubMed ID: 29524348
[TBL] [Abstract][Full Text] [Related]
12. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.
Lonial S; Vij R; Harousseau JL; Facon T; Moreau P; Mazumder A; Kaufman JL; Leleu X; Tsao LC; Westland C; Singhal AK; Jagannath S
J Clin Oncol; 2012 Jun; 30(16):1953-9. PubMed ID: 22547589
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of elotuzumab for the treatment of multiple myeloma.
Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
Expert Opin Drug Saf; 2017 Feb; 16(2):237-245. PubMed ID: 28060563
[TBL] [Abstract][Full Text] [Related]
14. Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma.
Lamb YN
Drugs; 2018 Sep; 78(14):1481-1488. PubMed ID: 30232695
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
Afifi S; Michael A; Lesokhin A
Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
[TBL] [Abstract][Full Text] [Related]
16. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials.
Martino EA; Palmieri S; Galli M; Derudas D; Mina R; Della Pepa R; Zambello R; Vigna E; Bruzzese A; Mangiacavalli S; Zamagni E; Califano C; Musso M; Conticello C; Cerchione C; Mele G; Di Renzo N; Offidani M; Tarantini G; Casaluci GM; Rago A; Ria R; Uccello G; Barilà G; Palumbo G; Pettine L; Vincelli ID; Brunori M; Accardi F; Amico V; Amendola A; Fontana R; Bongarzoni V; Rossini B; Cotzia E; Gozzetti A; Rizzi R; Sgherza N; Reddiconto G; Maroccia A; Franceschini L; Bertuglia G; Nappi D; Barbieri E; Gamberi B; Petrucci MT; Di Raimondo F; Neri A; Morabito F; Musto P; Gentile M
Hematol Oncol; 2024 Jul; 42(4):e3290. PubMed ID: 38818978
[TBL] [Abstract][Full Text] [Related]
17. Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan.
Kubo K; Hori M; Ohta K; Handa H; Hatake K; Matsumoto M; Hagiwara S; Ohashi K; Nakaseko C; Suzuki K; Ito S; Kinoshita G; Shelat SG; Miyoshi M; Takezako N
Int J Hematol; 2020 Jan; 111(1):65-74. PubMed ID: 31701481
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.
Jakubowiak A; Offidani M; Pégourie B; De La Rubia J; Garderet L; Laribi K; Bosi A; Marasca R; Laubach J; Mohrbacher A; Carella AM; Singhal AK; Tsao LC; Lynch M; Bleickardt E; Jou YM; Robbins M; Palumbo A
Blood; 2016 Jun; 127(23):2833-40. PubMed ID: 27091875
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
[TBL] [Abstract][Full Text] [Related]
20. Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study.
Leng Y; Hou J; Jin J; Zhang M; Ke X; Jiang B; Pan L; Yang L; Zhou F; Wang J; Wang Z; Liu L; Li W; Shen Z; Qiu L; Chang N; Li J; Liu J; Pang H; Meng H; Wei P; Jiang H; Liu Y; Zheng X; Yang S; Chen W
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1141-1149. PubMed ID: 28500554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
